NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.

EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC

Now Viewing

EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer

EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

EP: 7.Final Insights on Current Bladder Cancer Clinical Trials

Video content above is prompted by the following question(s):

• Describe the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in MIBC. What were the key efficacy results in terms of pathologic complete response and major pathologic response rates?

Related Videos

Related Content

Advertisement

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Maggie L. Shaw

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

Maggie L. Shaw

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH

Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.

Related Content

Advertisement

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Maggie L. Shaw

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

Maggie L. Shaw

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH

Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.